Emerging applications of nanotechnology for diagnosis and therapy of disease: a review by Bayford, Richard et al.
Middlesex University Research Repository
An open access repository of
Middlesex University research
http://eprints.mdx.ac.uk
Bayford, Richard and Rademacher, Tom and Roitt, Ivan and Wang,
Scarlet Xiaoyan (2017) Emerging applications of nanotechnology for
diagnosis and therapy of disease: a review. Physiological
Measurement, 38 (8). ISSN 0967-3334 
http://dx.doi.org/10.1088/1361-6579/aa7182
Final accepted version (with author's formatting)
Available from Middlesex University’s Research Repository at
http://eprints.mdx.ac.uk/21772/
Copyright:
Middlesex University Research Repository makes the University’s research available electronically.
Copyright and moral rights to this thesis/research project are retained by the author and/or 
other copyright owners. The work is supplied on the understanding that any use for 
commercial gain is strictly forbidden. A copy may be downloaded for personal, 
non-commercial, research or study without prior permission and without charge. Any use of 
the thesis/research project for private study or research must be properly acknowledged with
reference to the work’s full bibliographic details.
This thesis/research project may not be reproduced in any format or medium, or extensive 
quotations taken from it, or its content changed in any way, without first obtaining permission
in writing from the copyright holder(s).
If you believe that any material held in the repository infringes copyright law, please contact 
the Repository Team at Middlesex University via the following email address:
eprints@mdx.ac.uk
The item will be removed from the repository while any claim is being investigated.
Emerging	applications	of	nanotechnology	for	diagnosis	and	therapy	of	disease:	a	review		 Authors:	Richard	Bayford,	Tom	Rademacher,	Ivan	Roitt	and	Scarlet	Xiaoyan	Wang	Correspondence	r.bayford@mdx.ac.uk		
Abstract:	 Nanotechnology	 is	 of	 increasing	 interest	 in	 the	 fields	 of	 medicine	 and	physiology	 over	 recent	 years.	 Its	 application	 could	 considerably	 improve	 disease	detection	and	therapy,	and	although	the	potential	is	considerable,	there	are	still	many	challenges,	which	need	 to	be	 addressed	before	 it	 is	 accepted	 in	 routine	 clinical	 use.	This	review	focuses	on	emerging	applications	that	nanotechnology	could	enhance	or	provide	new	approaches	in	diagnoses	and	therapy.	The	main	focus	of	recent	research	centres	 on	 targeted	 therapies	 and	 enhancing	 imaging;	 however,	 the	 introduction	 of	nanomaterial	into	the	human	body	must	be	controlled,	as	there	are	many	issues	with	possible	 toxicity	 and	 long-term	 effects.	 Despite	 these	 issues,	 the	 potential	 for	nanotechnology	 to	 provide	 new	 methods	 of	 combating	 cancer	 and	 other	 disease	conditions	is	considerable.	There	are	still	key	challenges	for	researchers	in	this	field,	including	 the	 means	 of	 delivery	 and	 targetting	 in	 the	 body	 to	 provide	 effective	treatment	for	specific	disease	conditions.	 	Nanoparticles	are	difficult	to	measure	due	to	 the	 size	 and	 physical	 properties;	 hence	 there	 is	 still	 a	 great	 need	 to	 improve	physiological	measurements	method	in	the	field	to	ascertain	how	effective	their	use	is	in	the	human	subject.	This	review	is	a	brief	snapshot	into	the	fast	changing	research	field	of	measurement	and	physiological	 links	to	nanoparticle	use	and	its	potential	 in	the	future.		
		
1	Introduction:	In	recent	years	the	use	of	nanotechnology	has	advanced	considerably	in	the	medical	field.	It	is	generally	defined	as	the	manipulation	of	matter	on	an	atomic,	molecular,	or	supramolecular	scale	in	the	order	of	one	dimension	less	than	100nm.	It	can	also	be	considered	as	the	understanding	and	control	of	the	processes	within	these	structures	sized	between	1	–	100	nanometers	(nm)	(Kumara	et	al	2014)	[1](Figure	1)		
	
	
	
		Figure	1.	Example	of	 size	 range	of	gold	nanomolecules,	plasmonic	Faradaurates	and	nanoparticles.	 A.	 Gold	 nanomolecules	 with	 size	 range	 between	 1	 and	 100	 nm.	 B.	Thiolated	 gold	 nanomolecules	 with	 a	 precise	 number	 of	 metal	 atoms	 and	 organic	ligands.	 C.	 Indication	 of	 the	 transition	 between	 the	 fixed	 composition	 containing	nanomolecules	 	 with	 ±0	 Au	 atom	 variation	 and	 polydisperse	 Au~500±10(SR)~120±3	particles	with	a	±10	Au	atom	variation.	 			(Lund	 et.	 al.,	 2011)	 [2](Figure	 2).	 The	 term	 nanoparticle	 (NP)	 is	 often	 used	 to	describe	 these	structures,	but	 this	does	not	necessary	give	a	correct	perception	of	a	nanoparticle.	 These	 structures	 can	 also	 be	 considered	 as	 scaffolds	 formed	 of	 atoms	used	to	build	advance	structures;	for	example	57	atoms	of	Au	can	be	used	as	a	scaffold	on	which	further	atoms	can	be	attached	followed	by	the	addition	of	biological	ligands.	Nanoparticles	 can	 also	 be	 created	 using	 different	 composite	materials	 at	 the	Nano-scale,	 changing	 their	 physical	 properties.	 Importantly	 these	 properties	 do	 not	generally	coincide	with	larger	non-nanoscale	counterparts.		
Size	also	affects	the	NP	physical	properties	so	it	is	important	to	create	particles	with	consistent	structures	that	can	be	reproduced.		The	material	used	in	the	fabrication	of	the	nanoparticle	can	include	gold,	iron,	silver,	cerium,	titanium	dioxide,	silica,	carbon,	zinc,	 copper,	 nickel,	 magnesium	 and	 composites	 thereof.	 Gold	 is	 favoured	 in	 the	construction	 of	 nanoparticles	 as	 it	 is	 hydrophobic	 although	 normally	 gold	 is	
paramagnetic	which	can	cause	issues	when	they	are	used	as	contrast	agents.	The	very	first	report	of	a	water-soluble	gold	nanoparticle	was	2001	by	de	 la	Fuente	JM	et.	al.,	[3].	 Composite	 have	 been	 produced	 for	 example	 gold	 and	 gold-iron	 oxide	magnetic	glyconanoparticles	to	combine	the	advantage	of	gold	and	magnetics	properties.	(de	la	Fuente	el	al	2006)	[4]	
	The	balance	between	the	nanoparticle	physical	properties,	their	biocompatibility	and	the	evidence	that	there	are	no	cytotoxic	effects	is	key	to	their	successful	use	in	clinical	applications.	Another	 important	 feature	 is	 the	configuration	of	 the	 ligands	and	 their	interaction	with	 the	 atoms	 on	 the	 particle	 surface	 as	 they	 play	 a	 significant	 role	 in	determining	the	physiochemical	properties	of	the	NPs	and	therefore	their	interaction	with	the	human	body	and	biological	material.		
It	 is	 also	 worth	 noting	 that	 extensive	 efforts	 have	 been	 made	 to	 synthesize	 and	characterize	 nanoparticles	 at	 sizes	 smaller	 than	 6nm,	 which	 includes	 the	 core	 and	attached	 ligands	 (Figure	 1),	 as	 this	 is	 the	maximum	 size	 that	will	 pass	 through	 the	kidney.	This	 is	 size,	 charge	and	shape-dependent	due	 to	 the	unique	structure	of	 the	glomerular	capillary	wall.	A	globular	AuNP	with	a	hydrodynamic	diameter	 (HD)	<	6	nm	 can	 pass	 through	 the	 glomerular	 capillary	 wall	 easily,	 while	 it	 is	 difficult	 for	 a	large	one	(HD	>	8	nm)	to	cross	through	due	to	the	kidney	filtration	threshold	(KFT)	which	 is	 about	 5.5	 nm.	 Furthermore,	 the	 surface	 charges	 of	 a	 NP	 also	 play	 an	important	role	in	the	kidney	filtration:	a	positively	charged	NP	with	an	HD	(6–8	nm)	slightly	 larger	 than	KFT	can	pass	 the	kidney	 filtration	barrier	due	 to	 the	 favourable	charge	 interactions	with	 the	 glomerular	 capillary	wall	 which	 is	 negatively	 charged,	whereas	filtration	through	the	kidney	is	difficult	for	the	negatively	charged	or	neutral	NP	 with	 an	 HD	 of	 6–8	 nm.	 (Kumara	 et	 al	 2014)	 [1]	 provides	 an	 illustration	demonstrated	the	size	range	of	nanomolecules	to	nanoparticles	and	Faradaurates.			
	
		
		
	
	 	 (a)	 	 	 	 	 (b)	
Figure	2(a).	Example	of	a	glucose	nanoparticle,	with	double	C2	domain	family,	containing	two	calcium	and	phospholipid	binding	domains	in	its	C	terminus	and	(b)	structure	of	surface	coating	ligands.	(Lund	et	al)	[2]			 			The	 range	 of	 uses	 of	 different	 types	 of	 NPs	 are	 difficult	 to	 fully	 categorise,	 but	 this	review	will	mainly	focus	on	two	specific	areas,	therapy	and	diagnosis.	NPs	can	deliver	therapy	by	a	number	of	methods:	by	enhancement	of	radiotherapy	or	heating	to	cause	cell	death,	as	a	scaffold	to	construct	new	molecular	structures	to	help	target	or	deliver	drugs,	and	as	an	image	contrast	agent	to	identify	disease	conditions.	This	review	gives	a	brief	overview	of	some	of	these	areas.	
2	 Diagnostics:	 Imaging	 and	 point	 of	 care	 technologies	 are	 two	 specific	 areas	 that	could	benefit	from	the	application	of	NPs.	
	
2.1	 Imaging:	 In	 the	 case	 of	 imaging,	 a	 contrast	 agent	 that	 could	 associate	 with	tumours	through	bonding	of	the	NP	surface	ligands	to	the	cancer	biomarker	would	be	of	 significant	 use	 in	 tracking	 the	 application	 of	 diagnoses	 and	 therapy.	 However,	identification	of	 appropriate	 ligands	 that	bind	 to	 the	 cancer	biomarker	 is	 still	 a	 key	challenge.	 Contrast	 agents	 are	 often	 used	 to	 track	 particular	 physiological	 process	during	imaging	and	NPs	can	play	a	major	role	in	the	future	of	medical	diagnostics	due	to	 their	many	 advantages	 over	 the	 conventional	 contrast	 agents,	 such	 as	 controlled	biological	 clearance	 pathways,	 specific	 molecular	 targeting	 capabilities	 (Shilo	 et	 al,	2012)[5]	and	prolonged	blood	circulation	time,	providing	a	 longer	 time	 for	 imaging.	This	offers	an	advantage	over	contrast	agents	made	from	particles	larger	than	1	μm,	
	
which	are	cleared	rapidly	by	the	body's	reticuloendothelial	system	following	injection	into	the	bloodstream.			
2.2	MRI:	The	application	of	nanotechnology	 to	 the	 field	of	medical	 imaging	offers	a	number	 of	 advantages.	 In	 the	 case	 of	 MRI,	 iron-based	 NPs	 causes	 a	 change	 in	 the	magnetic	 field	 but	 gold-based	 NPs	 are	 non-paramagnetic	 and	 although	 they	 are	biological	compatible,	do	not	affect	the	contrast	of	the	tissues	or	blood.	MRI	contrast	agents	 require	 the	 proton	 relaxation	 to	 be	 altered	 and	must	 be	 able	 to	 perturb	 the	local	 magnetic	 field	 around	 the	 proton.	 The	 perturbing	 field	 in	 MRI	 of	 a	 super	paramagnetic	 particle	 is	 effective	 at	 up	 to	 50-times	 its	 diameter,	 and	 therefore	influences	water	protons	in	several	cell	layers	around	its	location	(Shilo	et.	al.,	2012)	[5].	 First	 generation	 magnetic	 nanoparticles	 (MNP)	 are	 already	 in	 clinical	 use	 and	second	generation	agents,	with	 longer	blood	half	 lives,	are	 likely	 to	be	approved	 for	routine	clinical	use	 in	 the	near	 future.	Similar	AuNPs	are	at	present	not	used	due	to	their	 non-magnetic	 properties,	 although	 there	 are	 Faradaic	 (generated	 by	 the	reduction	 or	 oxidation	 of	 some	 chemical	 substance	 at	 the	 Au)	 AuNPs	 which	 do	possess	magnetic	properties	that	have	the	potential	for	use	in	this	area	(Mohs	et.	al.,	(2010	)[6].	Superparamagnetic	MNRs	which	normally	consist	of	a	central	core	of	iron-oxide	surrounded	by	a	carbohydrate	or	polymer	coat	are	playing	an	important	role	in	a	number	of	MRI	image	systems,	for	example	cardiovascular	molecular	imaging.	The	size,	physical	properties	and	pharmacokinetics	of	MNPs	make	 them	highly	suited	 to	cellular	and	molecular	imaging	of	atherosclerotic	plaques	and	myocardial	injury.	They	have	a	 sensitivity	 in	 the	nanomolar	 range	and	 can	be	detected	with	T1,	T2,	T2*,	 off	resonance	 and	 steady	 state	 free	 precision	 sequences	 that	 are	 used	 in	MRI	 systems.	Targeted	imaging	with	MNP	is	being	actively	explored	and	improvements	of	contrast-enhanced	magnetic	resonance	imaging	have	been	of	considerable	interest	(Xing,	et	al.	2014)	[7].		2.3	 PET:	 Radiolabeled	 positron-emitting	 isotopic	 nanoparticles	 for	 non-invasive	deciphering	 of	 biological	 events,	 such	 as	 tumor	 receptor	 levels	 and	 tumor	 enzyme	activities	have	been	developed	(Pérez-Campaña,	et.	al.,	2013)	[8];	for	example,	metal	oxide	 nanoparticles	 have	 been	 widely	 used	 for	 the	 construction	 of	 PET	 imaging	probes.	Perez–Campana	used	them	for	the	activation	of	18O–enriched	aluminum	oxide	(Al2O3)	 nanoparticles	 by	 irradiation	 with	 protons	 to	 yield	 18F–labeled	 NPs	 via	 the	18O(p,n)18F	nuclear	reaction	.		
2.4	 Ultrasound:	 A	 number	 of	 researchers	 have	 investigated	 the	 use	 of	 NPs	 for	
ultrasound	 imaging.	 Solid	 NPs	 can	 enhance	 ultrasonic	 grey	 scale	 images	 in	 tissue	phantoms	 and	 mouse	 livers	 in	 vivo.	 For	 example,	 silica	 nanospheres	 (100	 nm)	dispersed	 in	 agarose	 at	 1-2.5%	 mass	 concentration	 can	 be	 imaged	 by	 a	 high-resolution	ultrasound	 imaging	 system	 (transducer	 centre	 frequency:	30	MHz).	 They	also	 investigated	 polystyrene	 particles	 of	 different	 sizes	 (500-3000	 nm)	 and	concentrations	 (0.13-0.75%	 mass),	 which	 were	 similarly	 dispersed	 in	 agarose	 and	imaged.	(Liu	et.	al.,	2006)	[9].			
The	 potential	 use	 of	 platinum	 nanoparticles	 (Pt-NPs),	 as	 a	 superoxide	 dismutase	(SOD)/catalase	mimetic	antioxidant,	has	been	studied	by	Jawaid,	P.,	et.	al.,	[10]	The	Pt-NPs	in	combination	with	1MHz	ultrasound	at	an	intensity	of	0.4	W/cm(2),	10%	duty	factor,	 100	 Hz	 PRF,	 for	 2	 min	 promoted	 apoptosis	 in	 human	 myelomonocytic	lymphoma	U937	 cells	 assessed	 by	DNA	 fragmentation	 assay,	 cell	 cycle	 analysis	 and	Annexin	 V-FITC/PI	 staining.	 Cell	 counting	 and	 microscopic	 examination	 confirmed	cell	death.	The	mitochondrial	and	Ca(2+)-dependent	pathways	were	also	investigated.	These	 studies	 addressed	 the	 issue	 of	 the	 mechanisms	 of	 cell	 death	 following	therapeutic	ultrasound	treatment	in	the	presence	or	absence	of	Pt-NPs.	The	important	conclusion	was	 that	 Pt-NPs	 appeared	 to	 interfere	with	 apoptosis	 and	 consequently	block	 ultrasound-induced	 autophagy,	 this	 paradoxically	 led	 to	 increased	 cell	 killing.	The	 authors	 concluded	 that	 autophagy	 induced	 after	 ultrasound	mechanical	 effects	operates	 	“pro-survival	pathway”	and	its	blockade	by	Pt-NPs	causes	enhancement	of	cell	killing.	
		
2.5	CT:	Enhancement	of	particular	regions	in	the	human	body	would	be	of	great	value	for	diagnosing	a	range	of	disease	conditions.	Considerable	research	is	focusing	on	the	development	 of	 nanoparticle	 CT	 contrast	 agents	 for	 molecular	 imaging	 of	 blood	 (	pooling	which	occurs	when	the	walls	and	valves	of	veins	in	human	legs	do	not	work	effectively,	 thereby	making	 it	difficult	 for	blood	 to	 return	 to	 the	heart).	 	Each	 image	modality	 uses	 different	 physical	 principles	 to	 obtain	 the	 image,	 and	 require	 the	physical	 properties	 of	 the	 contrast	 agent	 to	 be	 compatible	 with	 the	 physics	 of	 the	specific	 imaging	 system.	Most	 CT	 contrast	 agents	 lack	 this	 amplification	 ability	 and	force	 and	 since	 CT	 imaging	 requires	 millimolar	 contrast	 agent	 concentrations	 to	induce	 sufficient	 contrast	 in	 the	 desired	 organ,	 a	 much	 larger	 amount	 is	 needed.	
However,	nanoparticle	contrast	agents	can	amplify	the	contrast,	which	would	allow	a	reduction	in	the	relatively	high	radiation	exposure	of	CT.	Thus,	these	new	generation	CT	contrast	agents	based	on	high	atomic	number	materials,	such	as	gold	and	bismuth,	have	a	great	potential	not	only	because	of	their	ability	to	produce	higher	contrast	than	conventional	iodine-based	contrast	agents,	but	even	more	importantly,	because	of	the	potential	 to	 lower	 the	 overall	 radiation	 exposure	 to	 patients.	 Hainfeld	 et	 al.	(2004)[11]	 studied	molecular	 imaging	 of	 cancer	 with	 actively	 targeted	 CT	 contrast	agents.	They	showed	that	AuNPs	can	enhance	the	visibility	of	mm-sized	xenografted	human	 breast	 tumors	 in	 mice,	 and	 that	 active	 tumor	 targeting	 (with	 anti-Her2	antibodies)	is	1.6-fold	more	efficient	than	passive	targeting.	They	also	demonstrated	that	 the	 specific	 uptake	 of	 the	 targeted	 AuNPs	 in	 the	 tumor	 periphery	was	 22-fold	higher	 than	 in	 surrounding	muscle.	 Chanda	et	al.	(2010)[12]	 reported	 enhanced	CT	attenuation	 of	 bombesin-functionalized	 AuNPs	 that	 selectively	 targeted	 cancer	receptor	 sites	 that	 are	 overexpressed	 in	 prostate,	 breast	 and	 small-cell	 lung	carcinoma	 while	 Mottiei	 et.	 al.	 (2016)	 [13]	 recently	 investigated	 methods	 to	differentiate	 between	 cancer	 and	 inflammation	 during	 functional	 computed	tomography	since	PET	scanning	using	18F	glucose	is	unable	to	distinguish	between	an	inflammatory	 lesion	 and	 a	 cancer	 lesion	 as	 both	 have	 increased	 glucose	 metabolic	associated	uptake.	 	They	 found	that	glucose	AuNPs	can	act	as	a	CT	agent	and	which	allows	for	the	differentiation	between	cancer	and	an	inflammatory	process.		Although	new	research	papers	are	continuously	being	published	in	this	area	the	key	challenge	 is	 the	 acceptance	of	 their	use	 in	humans,	which	 requires	more	 studies	on	the	long-term	effect	of	the	NPs.		
2.6	 Point-of-Care:	 A	 promising	 area	 in	 diagnostics	 is	 the	 development	 of	 point-of-care	biosensor	devices.	Point-of-Care	devices	for	a	range	of	diagnoses	is	an	expanding	research	 field	particularly	where	 there	 is	 a	 need	 for	high	 specificity	 and	 sensitivity.	AuNPs	 can	 be	 used	 to	 enhance	 this	 for	 a	 range	 of	 applications	 for	 example	 in	 an	electrical	 biosensor	 they	 can	 be	 applied	 to	 the	 surface	 to	 effectively	 increase	 the	surface	 area	 of	 the	 sensor	 and	 so	 increase	 the	 sensitivity.	 There	 are	 a	 number	 of	groups	 developing	 these	 with	 AuNPs.	 These	 include	 detection	 of	 human	phospholipase	 A2	 in	 pancreatitis,	 aggregation	 and	 self-association	 of	 monoclonal	antibodies	(Li	et.	al.,	2013)	 [14],	milk	contamination	using	alkaline	phosphatase	(Yu	et.	 al.,	 2015)	 [15]	 and	 anti-tumour	 antibodies	 for	 the	 diagnosis	 of	 prostate	 cancer	(Zheng	et.	al.,	2014)[16].			
		
3.	 Therapy:	 	 The	 use	 of	 NPs	 for	 therapy	 is	 probably	 the	 most	 important	 area	 of	development	in	NP	research.	The	ability	to	enhance	or	improve	the	delivery	of	target	therapy	is	considerable	and	some	of	the	most	promising	findings	are	detailed	below:		
3.1	 Cancer:	 Cancer	 is	 one	 of	 the	 largest	 areas	 in	which	NPs	 are	 beginning	 to	 show	promising	 developments.	 Many	 cancer	 patients	 survive	 treatment	 only	 to	 have	 a	recurrence	 within	 a	 few	 years.	 Recurrences	 and	 tumor	 spreading	 are	 often	 due	 to	cancer	 stem	 cells	 that	 can	 be	 resistant	 to	 killing	 by	 conventional	 cancer	 drugs.	 But	now	researchers	have	designed	NPs	that	specifically	target	these	hardy	cells	to	deliver	a	drug.		The	hope	is	the	NPs	will	target	the	cancer	for	both	imaging	and	therapy.	For	example,	 Poon	 et.	 al.,	 2015	 [17]	 demonstrated	 passively	 targeted	NPs	 to	melanoma	using	either	cyclic	RGD	peptide	or	a	peptide	from	a	cancer-seeking	myxoma	virus.	Lai	et	al.,	2015	[18]	used	AuNPs	as	a	multimodality	imaging	agent	for	brain	glioma.		They	present	results	that	not	only	identify	primary	glioma	but	also	follow	the	development	of	the	glioma	with	time	and	most	importantly	reveal	full	details	of	the	tumour	related	microvasculature.	 They	 observed	 leaking	 of	 AuNPs	 from	 the	 tumour-related	vasculature	in	contrast	to	no	leakage	from	normal	vasculature.			Radiation	 therapy	 along	with	 surgery	 and	 chemotherapy	 are	 the	major	 therapeutic	strategies	 for	 cancer	 treatment.	 Unfortunately	 the	 development	 of	 resistance	 to	 the	therapeutic	modality	is	a	major	reason	for	the	absence	of	cure	and	subsequent	tumor	growth.	 It	 requires	 the	 delivery	 of	 high	 intensity	 ionizing	 radiations	 with	 high	accuracy	to	the	tumor	tissue	resulting	in	the	death	of	tumor	cells.	Radiation	therapy	has	 its	 disadvantages	 including	 the	 possibility	 of	 injury	 to	 the	 surrounding	 normal	tissue.	Another	disadvantage	is	that	some	tumor	cells	are	farther	away	from	the	site	of	radiation	and	hence	might	receive	a	lower	intensity	of	the	radiation	beam.	Moreover,	the	 cells	 can	 develop	 resistance	 to	 the	 radiation.	 Usually	 the	 sensitivity	 of	 the	mitotically	active	tumor	cells	is	only	slightly	higher	than	that	of	surrounding	healthy	tissue	so	that	the	minimum	dose	of	radiation	that	is	sufficient	to	kill	tumor	tissue	may	only	injure	but	not	kill	the	normal	tissue.	However,	due	to	development	of	resistance	of	 tumor	 cells	 to	 the	 dosed	 radiation	 results	 in	 the	 requirement	 of	 elevated	 doses	which	eventually	leads	to	death	of	the	healthy	tissue.	
Multiple	 approaches	 have	 been	 utilized	 to	 limit	 the	 radiation	 resistance	 while	
simultaneously	 enhancing	 the	 efficacy	 and	 safety	 of	 radiation	 therapy.	 The	 three	major	 approaches	 for	 the	 improvement	 of	 radiation	 therapy	 have	 involved	 (a)	enhancing	radiosensitization	of	tumor	tissue;	(b)	reversing	of	radiation	resistance	in	tumor	tissue;	and	(c)	enhancing	radio	resistance	of	the	healthy	tissue.	(Kwatra	et.	al.,	2013)[19].	 As	 with	 all	 forms	 of	 cancer	 treatment	 the	 aim	 of	 radiotherapy	 is	 to	selectively	maximise	tumour	killing	while	reducing	the	damage	to	healthy	tissue.	The	first	demonstration	of	AuNPs	was	present	by	Hainfeld	et.	al.,	(2004)[20].		AuNP	radio	enhancement	 has	 become	 an	 increasing	 area	 of	 investigation	 as	 an	 approach	 to	increase	 the	 effectiveness	 of	 ionising	 radiation	 in	 biological	 systems.	 The	biocompatibility	 is	 ideal	 although	 there	 is	much	work	 still	 required	 to	 improve	 the	targeting	of	AuNPs	at	tumor	sites	to	make	it	an	ideal	therapeutic	contrast	agent.	Au’s	radiosensitization	 is	 due	 to	 its	 increased	 photoelectric	 absorption	 cross	 section	 in	comparison	 to	 that	 of	 the	 surrounding	 cells.	 During	 irradiation,	 this	 results	 in	 an	enhancement	of	the	energy	deposition	in	the	vicinity	of	the	gold	particles	due	to	the	generation	of	photoelectrons,	Auger	electrons,	and	characteristic	X-rays.		
Recently,	McQuaid	et.al.,	(2016)[21]	presented	the	first	experimental	results	that	take	into	account	both	 the	measured	biodistribution	of	 gold	nanoparticles	 at	 the	 cellular	level	 and	 the	 range	 of	 the	 product	 electrons	 responsible	 for	 energy	 deposition.	Combining	 synchrotron-generated	 monoenergetic	 X-rays,	 intracellular	 gold	 particle	imaging	and	DNA	damage	assays,	enabled	a	DNA	damage	model	to	be	generated	that	includes	the	production	of	intermediate	electrons.	This	is	an	important	result	as	it	is	the	 first	 time	 good	 agreement	 between	 the	 predictions	 of	 biological	 outcomes	 from	both	 the	 Local	 Effect	 Models	 has	 been	 presented	 using	 a	 DNA	 damage	model	 with	experimentally	observed	cell	killing	and	DNA	damage	 induction	via	the	combination	of	X-rays	and	GNPs.	Two	distinct	models	as	 indicated	by	this	mechanistic	study,	one	for	 short-term	DNA	damage	and	another	 for	 cell	 survival,	 indicates	 that,	 at	 least	 for	nanoparticle	 enhancement,	 it	 is	 not	 safe	 to	 equate	 the	 lethal	 lesions	 invoked	 in	 the	local	 effect	 model	 with	 DNA	 damage	 events.	 mostly	 Auger,	 electrons.	 The	 AuNP	efficacy	in	this	application	is	due	to	the	enhanced	secondary	emission	of	 low-energy	electrons	(mostly	Auger	electrons).			Researchers	such	as	Brivio	et	al.,(2015)	[22]	 	 investigated	the	concept	of	kilovoltage	radiosurgery	 with	 AuNPs	 for	 AMD	 (Age-related	 Macular	 Degeneration).	 They	concluded	 that	a	prescribed	dose	of	x-ray	radiation	could	be	delivered	using	almost	half	 of	 the	 radiation	 when	 compared	 to	 a	 treatment	 without	 AuNPs	 allowing	
reduction	of	the	dose	delivered	to	the	neighbouring	organs	such	as	the	retinal/optic	nerve	 by	 49%.	 Dou	 et.	 al.,	 (2015)	 [23]	 looked	 at	 the	 optimal	 size	 for	 simultaneous	enhanced	 CT	 imaging	 and	 radiotherapy.	 Using	 the	 enhanced	 permeability	 and	retention	 EPR	 effect	 to	 get	 the	 larger	 particles	 trapped	 in	 the	 stroma	 around	 the	tumour,	 they	 studied	 particles	 in	 the	 range	 of	 3-50nm	 and	 concluded	 that	 13nm	particles	 were	 optimal	 for	 the	 dual	 application.	 Irani	 et.	 al.,(2015)	 [24]	 found	 that	AuNPs	 can	 enhance	 growth	 arrest	 in	 colorectal	 cancer	 cells	 when	 they	 are	 treated	with	cold	plasma	(Plasma	can	be	divided	 into	two	broad	categories:	 thermal	plasma	and	 non-thermal	 or	 cold	 plasma.	 Cold	 plasma	may	 also	 refer	 to	 the	 barely	 ionized	plasma	(e.g.,	1%))	as	indicated	in	section	3.1	It	is	of	interest	that	radiotherapy,	proton	therapy	and	also	cold	plasma	therapy	are	all	enhanced	by	AuNPs.	This	suggests	that	a	single	 tumour-targeting	 compound	 could	 be	 used	 independently	 of	 the	 external	therapy	applied.		Also,	as	mentioned	in	Section	3.1	Popovtzer	et..	al.,(2016)	[25]	found	that	 actively	 targeted	 gold	 AuNPs	 as	 radio	 sensitizers	 for	 head	 and	 neck	 cancer	produced	 radiation	 enhancement	 which	 was	 secondary	 to	 greater	 apoptosis,	angiogenesis	inhibition	and	diminished	DNA	repair.	No	toxicity	was	observed	for	the	conjugates	prior	to	irradiation.			Cheng	 et	 al.,	 2014	 [26]	 demonstrated	 that	 NPs	 have	 a	 synergistic	 effect	 with	 cold	plasma.	The	addition	of	the	NPs	decreased	cell	viability	allowing	the	cold	plasma	to	be	more	 efficient.	 This	 is	 another	 example	 of	 how	 NPs	 can	 be	 used	 as	 synergistic	reagents	with	 various	 cancer	 therapeutic	 techniques	 such	 as	 the	 radio	 sensitisation	for	proton	therapy	and	now	cold	plasma	therapy.	The	fact	that	radiotherapy,	proton	therapy	and	also	cold	plasma	therapy	are	all	enhanced	by	NPs,	suggests	that	a	single	tumour-targeting	 compound	 could	 be	 used	 independently	 of	 the	 external	 therapy	applied,	but	targeting	is	key	to	the	success	of	this	method.			A	pioneering	study	by	Simon	et.	al.,	2015	[27]	selected	 four	drugs	that	are	normally	used	for	the	treatment	of	acute	myeloid	leukaemia,	lestaurtinib,	midostatin,	sorafenib	and	 quizartinib.	 Their	 study	 demonstrates	 superior	 cytotoxicity	 of	 the	 nano-conjugates	 compared	 with	 the	 free	 drugs.	 It	 is	 estimated	 that	 the	 vast	 majority	 of	drugs	are	not	developed	because	of	physicochemical	problems	such	as	solubility	and	stability.	 Other	 researchers	 have	 developed	 a	 small	 molecule	 inhibitor	 for	 Rad6,	 a	protein	over-expressed	 in	aggressive	breast	 cancers	 (Haynes	et.	 al.,	 2016	 [28]).	The	inhibitor	induces	cytotoxicity	in	cancerous	cells	but	spares	normal	breast	cancer.	The	therapeutic	 effect	 however	 is	 limited	 by	 poor	 solubility.	 They	 demonstrate	 that	
attachment	to	AuNPs	provides	a	soluble	delivery	vehicle	for	the	drug	and	is	active	and	induces	mitochondrial	cell	death	via	mitochondrial	dysfunction.	They	also	suggested	it	could	also	have	synergistic	actions	with	cisplatin.	Yang	et.	al.,	2016	[29]	found	that	tumour	 angiogenesis-targeted	 radiosensitization	 therapy	 using	 beams	 of	 ionizing	radiation	 was	 enhanced	 by	 the	 cyclic	 RGDyC	 (http://www.creative-peptides.com/product/rgdyc-item-r04013-18265.html)	peptide	conjugated	to	AuNPs	which	included	gadolinium	(Gd)	and	99mTc-exametazime,	a	radiopharmaceutical	sold	under	 the	 trade	 name	 Ceretec	 and	 is	 used	 by	 nuclear	 medicine	 physicians	 for	 the	detection	of	altered	regional	 cerebral	perfusion	 in	stroke	and	other	cerebrovascular	diseases.	It	can	also	be	used	for	the	labelling	of	leukocytes	to	localise	intra-abdominal	infections	 and	 inflammatory	 bowel	 disease.	 Exametazime	 (the	 part	 without	technetium),	 sometimes	 referred	 to	 by	 its	 chemical	 name	 of	
hexamethylpropyleneamine	 oxime	 (or	 HMPAO),	 is	 used	 to	 guide	 the	 therapy	 by	MRI/SPECT	 imaging.	 AuNPs	 RGD	 probes	 are	 clearly	 of	 considerable	 use	 as	radiosensitizers	capable	of	guiding	and	enhancing	radiotherapy	of	tumours.			
Many	cancer	treatments	rely	on	combination	of	CT	with	radiotherapy.	Dou	et	al.,	2016	[23]	 estimated	 the	 optimal	 size	 for	 simultaneously	 enhanced	 CT	 imaging	 and	radiotherapy.	They	used	the	Enhanced	Permeability	and	Retention		(EPR)	effect	to	get	the	 larger	 particles	 trapped	 in	 the	 stroma	 around	 the	 tumour.	 	 Particles	 were	investigated	in	the	range	of	3-50nm	and	they	concluded	that	13nm	particles	were	the	optimum	for	the	dual	application.		
	A	 number	 of	 investigators	 have	 studied	 the	 use	 of	 AuNPs	 for	 specific	 cancers.	Enhanced	 growth	 arrest	 of	 colorectal	 cancer	 cell	 occurred	 when	 treated	 with	 cold	plasma	 (Irani	 et.	 al.,	 2015[24]).	 Popovtzer	 et	 al.,	 2016	 [25]	 demonstrated	 actively	targeted	 AuNPs	 with	 radio	 sensitizers	 for	 head	 and	 neck	 cancer.	 As	 with	 many	previous	 studies	 they	 demonstrated	 radiation	 enhancement.	 The	 mechanism	 of	enhancement	 appears	 to	 be	 a	 consequence	 of	 greater	 apoptosis,	 angiogenesis	inhibition	 and	 diminished	 DNA	 repair.	 No	 toxicity	was	 observed	 for	 the	 conjugates	prior	to	irradiation.	Acute	myeloid	leukaemia	is	another	condition	that	could	benefit	from	 the	 use	 of	 NPs.	 The	main	 therapeutic	 strategy	 uses	 tyrosine	 kinase	 inhibitors	and	 two	 thirds	 of	 patients	 achieve	 complete	 remission	 but	 most	 will	 ultimately	relapse.	 Petrushev	 et.	 al.,	 2016	 [30]	 demonstrated	 that	 when	 these	 drugs	 are	
conjugated	 to	 AuNPs	 they	 are	 superior	 to	 the	 free	 drugs	 with	 regards	 to	 cellular	internalization,	 cell	 biology,	 etc.	 They	 validated	 transmembrane	 delivery	 and	increased	 efficacy.	 Song	 et	 al.,	 2016	 [31]	 investigated	 the	 use	 of	 endothelial	 growth	factor	(EGF)	conjugated	AuNPs		synthesized	via	the	citrate	reduction	method	and	then	conjugated	 with	 chelating	 ligand	 DTPA-coupled	 EGF	 forming	 EGF-AuNP	 which	enabled	targeted	delivery	of	a	highly	radioactive	payload	specifically	to	EGFR-positive	cancer	cells	(e.g.	breast	cancer).	Fitzgerald	et	al.,	2016	[32]	investigated	anisamide	to	target	AuNPs	to	prostate	cancer.	They	claim	proof	of	principle	in	their	study	that	the	nanoparticles	 can	 be	 targeted	 to	 the	 sigma	 receptor	 which	 could	 be	 an	 important	finding	 if	 validated	 by	 others.	 Yook	 et	 al.,	 (2016)[33]	 also	 performed	 a	 very	interesting	 study	 looking	 at	 the	 stability	 and	 bio-distribution	 of	 thiol	 functionalized	nanoparticles	containing	Lu	(Lutetium)	for	radiation	treatment	of	breast	cancer.	It	is	the	 chemistry	 of	 the	 study	 that	 is	 clever.	 They	 coated	 the	 cell	 with	 functionalizing	reagents	 that	have	one,	 two	or	eight	 thiol	groups.	With	 increasing	 thiol	 content	one	would	 expect	 less	 ligand	 exchange	 and	 they	 confirmed	 that	 the	 eight	 thiol	 form	 is	indeed	 the	most	 stable	 but	 interestingly	 also	 has	 the	 lowest	 liver	 uptake	 (i.e.	 non-specific	 uptake).	 Another	 approach	 studied	 by	 Gomaa	 et	 al.,	 2015[34]	 on	 the	cytotoxicity	and	genotoxicity	of	AuNP	mediated	photo-thermal	 therapy	compared	to	the	 chemotherapeutic	 5-FU	 produced	 	 an	 interesting	 result;	 they	 found	 	 that	while	both	 methods	 resulted	 in	 equivalent	 cytotoxic	 effects,	 the	 5-FU,	 resulted	 in	chromosomal	aberrations	whereas	none	were	detected	with	the	AuNP	method.		
3.2	Delivery:	An	important	issue	for	the	use	of	NPs	is	the	delivery	of	agents	for	cancer	treatment;	 these	 include	 aptamer-modified	 AuNPs	 for	 the	 controlled	 release	 and	reversible	 delivery	 of	 daunorubicin	 (Taghdis,	 et.	 al.,	 2016	 [35]).	 Aptamers	 are	 ideal	AuNP	 targeting	 agents.	 Platinum	 drugs	 are	 by	 far	 the	 largest	 class	 of	 anti-cancer	agents	 and	 Johnstone	 et.	 al.,	 2013	 [36]	 produced	 an	 interesting	 review	 on	 the	 next	generation	 of	 platinum	 drugs	 using	 NP	 delivery.	 Monoclonal	 antibodies	 make	 an	important	 contribution	 to	 anti-cancer	 therapy	 and	 if	 AuNP	 can	 be	 shown	 to	generically	enhance	 the	performance	of	 the	drugs,	 this	could	be	a	major	use	of	NPs.	Indeed,	 Ma	 et.	 al.,	 2016	 [37]	 showed	 that	 the	 activity	 of	 a	 humanized	 mouse	monoclonal	 that	 had	 been	 developed	 to	 treat	 hepatocellular	 carcinoma	 could	 be	enhanced	by	conjugation	 to	AuNP.	 	Another	approach	 is	 the	use	of	AuNP	nanoseeds	for	 non-resectable	 solid	 tumour	 treatment	 (Moeendarbari	 et	 al.,	 2016	 [38]).	 These	constructs	consist	of	AuNPs	passivated	with	palladium	-103.	There	appear	to	be	many	reports	highlighting	the	use	of	nanoseeds	for	brachytherapy		
Although	 there	 is	 considerable	 evidence	 that	 NPs	 do	 have	 potential	 for	 cancer	therapy,	only	very	limited	human	trials	of	NPs	have	been	reported	essentially	due	to	the	need	for	long	term	studies	to	ascertain	any	future	toxicity	effects	on	patients	and	the	requirement	for	FDA	approval.	
		
3.3.	 Wound	 healing	 and	 burns:	 This	 area	 has	 considerable	 potential;	 a	 primary	objective	 in	 dermatology	 is	 to	 achieve	wound	 healing	without	 formation	 of	 scar	 or	even	 a	 faint	 scar.	 Naraginti	 et.	 al.,(2016)	 [39]	 have	 used	 green	 synthesized	 AuNPs	from	Coleus	forskohtii	to	look	at	wound	closure	in	rats.	Topical	formulations	of	the		AuNPs	promoted	wound	closure	and	reduction	in	excision	wounds	would	be	of	great	value	for	acute	wound	repair.	They	suggest	the	effect	could	be	secondary	to	the	now	established	 antimicrobial,	 antioxidant	 and	 anti-inflammatory	 properties	 of	 AuNPs.	Other	 groups	 (Ju	 et	 al.,	 2015)[40]	 have	 taken	 advantage	 of	 the	 anti-inflammatory	action	 of	 AuNPs	 and	 loaded	 electro-spun	 silk	 with	 AuNPs.	 Full	 thickness	 dermal	wound	 healing	 models	 were	 used	 and	 they	 demonstrated	 superior	 action	 for	 the	matrices	that	had	incorporated	AuNPs.	This	reduces	scar	tissue	and	enhances	matrix	properties	and	good	wound	closure	properties.	Another	application	in	wound	healing	concerns	 the	 surface	 of	 burns	 using	 a	 methylcellulose	 gel	 with	 or	 without	 AuNPs	(Volkova	et	al.,	2016)	[41].	This	accelerated	the	skin	synthetic	process	and	helped	in	recovering	Type	I	and	Type	II	collagen	content.	They	suggest	the	results	are	due	to	the	unique	 structure	and	antimicrobial	properties	of	AuNPs.	 	An	 important	need	 in	 this	research	 field	 is	 a	 means	 by	 which	 the	 progression	 of	 the	 wound	 healing	 can	 be	monitored.		NPs	could	provide	a	measure	of	this	by	labelling	them	with	a	fluorescent	(Pittet	et	al.,	2006)[42]	agent	allowing	an	optical	measurement	of	progress.	Methods	to	measure	the	biomarkers	using	NPs	in	the	wound	would	be	of	great	value.	
	
3.4	Cardiovascular	disease:	Restenosis	is	a	major	problem	in	cardiovascular	disease.	Khobchandani	 et.	 al.,	 (2016)	 [43]	 demonstrated	 that	 epigallacatechin-3-gallate	conjugated	NPs	 could	 be	 an	 alternative	 therapeutic	 approach	 to	 drug-coated	 stents	for	 preventing	 restenosis.	 They	 demonstrate	 that	 the	 AuNP	 conjugates	 are	internalized	 by	 avid,	 the	 laminin	 receptor;	 on	 human	 smooth	 muscle	 cell	 and	endothelial	cells.	If	this	type	of	NPs	can	be	imaged,	then	treatment	could	be	targeted	to	 specific	 parts	 of	 the	 cardiovascular	 system	 reducing	 the	 need	 for	 surgical	intervention.	 	 Apolipoprotein	 AI	 (ApoAI)	 and	 ApoB	 are	 risk	 indicators	 of	cardiovascular	 disease.	 Jiang	 et.	 al.,	 [44]	 describe	 the	 use	 of	 immunoresonance	
scattering	to	measure	the	ApoAI	and	ApoB	in	serum.	A	trisodium	citrate	method	was	used	 to	prepare	9.0-nm	gold	nanoparticles	 labeled	with	goat	anti-human	ApoAI	and	ApoB	antibodies.	The	immune	reaction	between	gold-labeled	antibodies	and	antigens	took	place	in	Na2HPO4-NaH2PO4	buffer	solution	(pH	6.4	for	ApoAI	and	pH	6.0	for	ApoB)	in	 the	 presence	 of	 75	 g/L	 polyethylene	 glycol	 (PEG).	 They	 used	 a	 transmission	electron	 microscope	 to	 observe	 the	 shape	 of	 the	 gold	 nanoparticles.	 The	 method	showed	high	sensitivity	and	good	selectivity	for	quantitative	determination	of	ApoAI	and	ApoB	in	human	serum.	
	
	
	
3.5	Neuroimmunology:	The	development	of	NPs	use	in	the	brain	is	of	considerable	interest	in	advancing	the	treatment	of	brain	disorders.	The	limitation	of	this	use	has	primarily	 been	 the	 difficulty	 of	 NPs	 passing	 the	 blood	 brain	 barrier	 (BBB).	 This	 is	meant	 to	 protect	 the	 brain	 from	 toxic	 agents,	 but	 unfortunately	 it	 also	 significantly	hinders	 the	delivery	 of	 therapeutics	 to	 the	brain.	A	number	of	 strategies	 have	been	employed	 to	 deliver	 drugs	 across	 this	 barrier	 and	 some	 of	 these	may	 do	 structural	damage	to	the	BBB	by	forcibly	opening	it	to	allow	the	uncontrolled	passage	of	drugs	(Jain	et.	al.,	2012	[45]).	Nanobiotechnology-based	delivery	methods	provide	the	best	prospects	 for	achieving	 this.	Some	strategies	require	multifunctional	NPs	combining	controlled	passage	across	the	BBB	with	targeted	delivery	of	the	therapeutic	cargo	to	the	intended	site	of	action	in	the	brain,	although	there	are	currently	some	limitations	and	concerns	for	the	potential	neurotoxicity	of	NPs.	 It	has	been	shown	that	the	size,	coating	and	surface	 charge	of	nanoparticles	have	a	 crucial	 impact	on	 the	passage	of	NP’s	across	the	BBB	and	subsequent	process	of	intracellular	uptake	process	(Shilo	et.	al.,	 2015	 [46]).	 Shilo	 et	 al.	 concluded	 that	 GNPs	 of	 size	 70	nm	 are	 optimal	 for	 the	maximum	 amount	 of	 gold	 within	 the	 brain	 cells,	 and	 that	 20	nm	 AuNPs	 are	 the	optimal	 size	 for	maximum	 free	 surface	area.	However,	 for	 the	NP	 to	pass	out	of	 the	kidney	 they	need	 to	be	5nm	or	 less.	Morris	et	 al.	 (2016)	 [47]	 reported	 results	 from	AuNPs	(15nm	diameter)	to	study	pathways	for	the	passage	of	fluid	into	and	out	of	the	brain.	 They	 concluded	 that	 cerebral	 vascular	 basement	 membranes	 form	 the	pathways	by	which	fluid	passes	into	and	out	of	the	brain	but	that	different	basement	membrane	layers	are	involved.		
	
3.6	 Antibiotics:	 Infections	 associated	 with	 medical	 devices	 are	 estimated	 to	 be	 a	multi-billion	dollar	burden	for	the	world-wide	healthcare	system.	Most	physiological	measurement	 devices	 require	 some	 patient	 contact,	 for	 example	 electrodes,	 which	have	to	be	disposable	to	reduce	the	risk	of	infection.	The	use	of	a	coating	could	reduce	the	cost	burden	on	the	healthcare	system.	Durán		et.	al.,	(2011)	[48]	have	produced	an	AuNP	 coating	 that	 incorporates	 an	 antimicrobial	 peptide	 which	 demonstrated	 high	antimicrobial	 activity	 against	 Gram	 positive	 and	 negative	 bacteria	 as	well	 as	multi-drug	resistant	bacteria.	The	coating	was	compatible	with	plasma	and	had	low	toxicity	to	 human	 cells	 and	 also	 did	 not	 induce	 platelet	 and	 complement	 activation.	 These	coatings	 can	 be	 transferred	 to	 glass,	 titanium,	 etc.	 and	 other	 substrates	 used	 in	medical	 devices.	 Other	 coatings	 include	 amoxicillin-coated	 AuNPs	 (Kalita	 et.	 al.,	2016)[49].	 These	 conjugates	 demonstrated	 broad-spectrum	 bactericidal	 activity	against	both	Gram	positive	and	negative	bacteria.	The	conjugates	also	showed	potent	anti-MRSA	 activity	 suggesting	 that	 by	 attaching	 the	 amoxicillin	 to	 the	 AuNPs	 there	was	 subversion	 of	 the	 antibiotic	 resistance	 mechanism.	 	 Mu	 et	 al.	 (2014)	 [50]	produced	chitosan-streptomycin	AuNP	conjugates	and	demonstrated	efficacy	against	Gram-negative	 bacterial	 biofilms.	 The	 conjugates	 were	 shown	 to	 inhibit	 planktonic	cell	 growth	 of	 these	 bacteria	 showing	 these	 conjugates	 can	 overcome	 antibiotic	resistance	of	microbial	biofilms.			
3.7	Tissue	engineering:	The	development	of	tissue	repair	is	of	considerable	interest	and	 its	 application	 in	 the	 repair	 of	 wound	 and	 organ	 or	 limb	 has	 seen	 many	advantages	 in	 recent	 years.	 The	 use	 of	 AuNP	 biomaterial	 patches	 composed	 of	decellularized	tissue	conjugated	to	AuNPs	has	been	shown	to	integrate	well	with	the	host	tissue	and	not	fail	over	the	six	month	implantation	time,	indicating	its	potential	applications	for	vascular	repair	and	blood	contacting	(Moravej	et.	al.,	2011)[51].	NPs	involved	 in	cardiac	 tissue	engineering	have	a	potential	 therapeutic	strategy	 for	end-stage	heart	failure	and	may	provide	new	solutions	to	the	serious	problems	of	shortage	of	 heart	 donors.	 For	 example,	AuNP-blended	polycaprolactone	 (PCL)	 scaffolds	were	found	to	enhance	mesenchymal	stem	cell	(MSCs)	proliferation	and	differentiation	into	cardiac	 tissue,	 making	 it	 a	 promising	 approach	 for	 repairing	 myocardial	 infarction	(Sridhar	et.	al.,	2015)	 [52].	Application	of	nanoparticles	 in	neural	 tissue	engineering	involves	 the	 utilization	 of	 a	 three-dimensional	 nanoscale	 nanoscaffold	 composed	 of	polymer	 fibres	 that	allows	damaged	cell	adherence	and	helps	rebuild	missing	 tissue	(Feng	et	al	2015)[53].	Carbon	nanotubes	have	been	increasingly	used	as	scaffolds	to	enhance	axon	regeneration	and	synaptogenesis	for	the	effective	treatment	of	central	
nervous	 system	 injuries	 due	 to	 their	 ability	 to	 promote	 neurone	 growth,	differentiation,	and	survival,	and	allow	the	modification	of	 their	electrophysiological	properties	 (Bokara	 et	 al.,	 2014)	 [54].	 For	 example,	 in	 a	 mammalian	 visual	 system	model,	 a	 designed	 self-assembling	 peptide	 nanofibre	 scaffold	 showed	 the	 ability	 to	regenerate	 axons	at	 the	 site	of	 an	acute	 injury	 and	knit	 the	brain	 tissue	 together	 to	promote	functional	return	of	vision	(Ruttledge	et	al.	2005)	[55].		
3.8	Toxicity:	It	is	important	to	consider	the	adverse	effects	such	as	potential	toxicity,	which	 is	 determined	 by	 various	 factors	 including	 particle	 size,	 shape	 and	 ability	 to	interact	 with	 the	 surrounding	 tissue.	 NPs	 may	 “overload”	 phagocytic	 cells,	 which	causes	a	defensive	fever	and	reduced	body	immunity.	NPs	may	be	difficult	to	degrade,	leading	 to	 accumulation	 in	 the	 organs.	 NPs	 may	 also	 affect	 enzymes	 and	 protein	activities	and	disturb	biological	processes	 in	the	body	due	to	their	high	surface	area		(Fang	 et.	 al.,	 2015)[56].	 Several	 possible	 mechanisms,	 such	 as	 oxidative	 stress,	autophagy,	 lysosome	 dysfunction,	 and	 the	 activation	 of	 certain	 signalling	 pathways,	may	 be	 involved.	 Researchers	 investigating	 the	 toxicity	 of	 NPs	 have	 carried	 out	 an	increasing	amount	of	research.	Recent	studies	suggested	that	NPs	induce	considerable	neurotoxicity	 in	 animals.	 For	 example,	 ZnO	 NPs	 were	 demonstrated	 to	 attenuate	learning	 and	memory	 ability	 in	 rats	 (Han	 et.	 al.,	 2011)[57].	 Another	 study	 in	 mice	suggested	 that	 TiO2	 nanoparticles	 accumulate	 in	 the	 mouse	 hippocampus	 after	intragastric	administration,	which	leads	to	hippocampal	apoptosis	and	impairment	in	spatial	 recognition	 (Ze	 et.	 al.,	 2014)	 [58].	 Furthermore,	 fatty	 degeneration	 of	 the	hippocampus	 and	 brain	 lesions	 was	 observed	 in	 mice	 after	 the	 injection	 of	 a	nanosized	TiO2	suspension	via	the	gastrointestinal	tract.	In	vivo	studies	have	indicated	that	 the	 neurotoxic	 effects	 of	 TiO2	 NPs	 on	 mice	 are	 likely	 to	 be	 attributed	 to	 the	disturbed	 homeostasis	 of	 trace	 elements,	 enzymes,	 and	 neurotransmitter	 systems	(Song	et.	al.,	2015)[59].	 In	addition,	silver	NPs	have	been	shown	to	cause	damage	to	the	BBB	and	astrocytes	and	induce	neuronal	degeneration	in	rats	after	subcutaneous	injection	(Xu	et.	al.,	2015)[60].	Polyamidoamine	coated	AuNPs	reduced	cell	metabolic	activity	 in	 algal	 and	 bacterial	 cells,	 but	 no	 change	 of	 mitochondrial	 activity	 in	mammalian	 cells	was	 observed	 after	 24	 hours	 of	 treatment	 (Perreault	 et	 al.,	 2014)	[61].	AuNPs	were	also	found	to	increase	endothelial	paracellular	permeability	in	vitro	and	 elevate	 BBB	 permeability	 in	vivo	 (Li	 et.	 al.,	 2015)(Gromnicova	 R,	 et.	 al.,	 2013)	[62][63].	Lee	U	et.	al.,	demonstrated	that	AuNPs	toxicity	is	dependent	on	the	dose	or	size	of	nanoparticles	administrated	into	the	brain	by	injection,	and	small	particle	size	AuNPs	induced	more	nestin	expression	compared	to	large	particle	size	at	short-term	
implantation	according	to	in	vitro	toxicity	and	in	vivo	gene	expression	studies.	Similar	results	were	found	in	the	research	on	10	nm	Fe-NPs,	indicating	a	neurotoxic	potential	of	very	small	size	iron	nanoparticles	and	use	of	these	ferric	oxide	NPs	could	result	in	neurotoxicity	(Syed	et.	al.,	2015)[64].			Some	 studies	 had	 investigated	 the	 impact	 of	 NPs	 on	 the	 reproductive	 system	 and	offspring.	 Mn2O3NPs	 were	 found	 to	 significantly	 reduce	 luteinizing	 hormone	 (LH),	follicle-stimulating	 hormone	 (FSH),	 and	 testosterone	 levels	 which	 results	 in	 a	significant	reduction	in	testicular	cytology	(Negahdary	et.	al.,	2015)[65].	Other	studies	indicated	that	the	inhalation	of	TiO2	NPs	led	to	long-term	lung	inflammation	in	mating	adult	mice,	and	their	offspring	exhibited	abnormal	neurological	behaviour	as	a	result	of	 the	 gestational	 exposure	 to	 NPs	 (Vandebriel	 et.	 al.,	 2012)[66].	 	 Naz	 et.	al.,(2016)[67]	examined	 the	bio-kinetics	of	 three	different	sizes	of	AuNPs	–	2,	5	and	10nm	diameter	and	followed	the	biokinetics,	redistribution	and	urinary	excretion	for	90	days.	No	mortality,	changes	in	behaviour,	hair	colour,	weight	and	food	intake	was	observed	 for	 the	 2nm	 particles.	 Neither	 was	 evidence	 for	 any	 significant	 changes	observed	 for	 haematocrit,	 serum	 biochemistry	 and	 tissue	 histology.	 Excretion	 was	predominantly	in	the	urine.		
4	The	role	of	NPs	in	the	delivery	and	intracellular	release	of	drug	conjugates	
4.1	Drug	 Vectorization:	The	 intracellular	penetration	of	a	drug	can	enable	optimal	efficacy	 of	 its	 active	 ingredients,	 especially	 in	 cases	 of	 multidrug	 resistance.	Vectorization,	 or	 drug	 transportation,	 systems	 consist	 of	 transporting	 biologically	active	molecules	 to	 their	 target	by	crossing	 the	biological	barriers	 to	administration	for	 example	 by	 the	 epithelium,	 endothelium,	 cell	membrane,	 as	well	 as	mechanical,	physico-chemical	and	enzymatic	barriers	 in	the	body.	A	number	of	researchers	have	devised	methods	to	overcome	this	problem	using	polyalkylcyanoacrylate	(PACA)	NPs	(Sulheim	et.	at.,	2016)[68].	The	blood	brain	barrier	has	been	of	considerable	interest	in	 recent	 year	 for	 application	 of	 drug	 vectorisation	 and	 imaging	 (see	 above	 section	3.5).	 Submicronic	 systems	 (nanoparticles,	 liposomes)	 for	 drug	 transport	 have	 been	used,	 in	 particular	 to	 treat	 hepatic	metastasis	 (Zhang	 et.	 al.,	 2014)[69].	 If	 improved	targeting	of	the	drug	to	increase	the	efficacy	of	the	treatment	could	be	achieved	then	the	side	effects	could	also	be	reduced.	For	example,	when	doxorubicin	is	transported	by	 biodegradable	 nanoparticles,	 its	 cardiac	 toxicity	 is	 greatly	 reduced	 (Gu	 et.	 al.,	2012)[70].	Also	biodegradable	porous	silicon	NPs	(pSiNP)	functionalised	with	cancer	cell	 targeting	 antibodies	 can	 also	 be	 loaded	with	 the	 hydrophobic	 anti-cancer	 drug	
camptothecin	(Secret	et.	al.,	2013)[71]		
4.2	Uptake	and	intracellular	fate	of	NP	constructs:	One	of	the	key	research	areas	at	present	 is	 uptake	 of	 NPs	 in	 cancer	 cells.	 Huang	 et.	 al.,	 (2010)	 [72]	 showed	 that	nutrient	 deprivation	 or	 an	 increase	 in	 the	 requirement	 of	 nutrients	 in	 tumour	 cells	can	promote	the	uptake	of	NP	from	the	microenvironment.		Like	Yang	et.	al.,	(Section		3.1)[29]	they	also	used	RGDyC	to	target	tumour	cells.	The	conjugates	also	contained	Pt(IV)	 as	 the	 cytotoxic	 agent.	 They	 found	 the	 constructs	 more	 active	 than	 the	 free	drug	and	were	able	to	show	that	the	increased	cytoxicity	was	due	to	cell	cycle	arrest.	This	 is	 a	 very	 different	 mechanism	 of	 action	 from	 that	 of	 the	 free	 drug.	 Volsi	 et.	al.,(2016)[73]	have	published	a	paper	that	demonstrates	that	if	AuNPs	are	passivated	with	 the	 polymer	 inulin	 there	 is	 enhanced	 delivery	 of	 the	 anti-cancer	 drug	doxorubicin	leading	to	preferential	accumulation	in	tumour	cells.	Experimentally	they	also	use	an	attractive	cancer/non-cancer	cell	co-culture	model.			A	 number	 of	 other	 researches	 have	 investigated	 the	 chemotherapeutic	 agent	doxorubicin	and	its	use	with	AuNPs	for	treatment	of	cancer	Dhamecha	et.	al.,	(2015)	[74]	 use	 a	 green	 method	 (involving	 biological	 and	 environmental	 safety	 of	 their	production.	The	main	methods	for	nanoparticle	production	are	chemical	and	physical	approaches	that	are	often	costly	and	potentially	harmful	to	the	environment)	to	make	the	AuNPs	loading	these	particles	with	doxorubicin.	They	showed	in	some	cancer	cell	lines	that	NP	constructs	had	greater	activity	than	the	free	doxorubicin.	Chaudhary	et.	al.,	 (2015)	 [75]	 demonstrated	 that	 they	 could	 achieve	 a	 single	 synthesis	 of	doxorubicin	 loaded	NPs.	 	 Showing	 that	 doxorubicin	 can	 act	 as	 both	 the	 passivating	agent	 and	 also	 the	 reducing	 agent	 removing	 the	 necessity	 of	 borohydride	 in	 the	synthesis,	 is	 a	 rather	 interesting	 approach.	 Interestingly,	 Curry	 et.	 al.,	 (2015)[76]	published	 almost	 simultaneously	 an	 empirical	 and	 theoretical	 paper	 proposing	 that	doxorubicin	could	itself	be	a	passivating	agent	for	gold	nanoparticles	as	was	actually	demonstrated	by	Chaudhary	et.	al.,	(2015)		[75]	above.		Another	key	area	in	the	targeting	of	nanoparticles	for	drug	delivery	is	the	loading	on	nanosystems	 by	 covalent	 conjugation	 or	 non-covalent	 interactions	 (Ulbrich	 et.	 al.,	2016)[77],	either	with	the	coating	or	directly	with	the	metallic	surface.	
			Figure	3.	Three	different	types	of	interactions	and	release	of	payloads	for	AuNPs		
This	 non-covalent	 approach	 employs	 active	 drugs	while	 the	 covalent	 attachment	 in	general	 requires	 intracellular	processing	 of	 a	 prodrug	 (Han	 et.	 al.,	 2011)	 [78].	 The	release	 of	 the	 attached	 payloads	 can	 be	 triggered	 by	 internal	 (endogenous)	or	external	 (exogenous)	 stimuli,	 such	 as	 high	 concentration	 of	glutathione	 which	would	 split	 S-S	 bond	 attachment	 (Ostdiek	 et.	 al.,	 2015)[79]	 or	 excitation	with	 light	(Sridhar	 et.	 al.,	 2015,	 Williamson	 et.	 al.,	 2013,	 Bokara	 et.	 al.,	 2013)	 [80,	 81,	 82],	respectively	 (Fig.	 3).	 Silva	 et	 al.	 (2016)	 [83]	 investigated	 the	 relative	 importance	 of	receptor-mediated	 uptake	 pathway	 of	 AuNPs	 compared	 to	 the	 EPR	 (Enhanced	permeability	 and	 retention)	 effect	 using	 bombesin	 peptide-functionalized	 gold	nanoparticles	in	a	human	prostate	model.	Interestingly,	they	found	the	EPR	effect	far	outweighs	 the	 receptor-mediated	 pathway.	 The	 above	 observation	was	 true	 for	 i.v.	administration	but	 in	contrast	 for	 i.p.	administration,	 the	peptide	receptor-mediated	mechanism	 played	 a	 significant	 role	 in	 pancreas	 uptake.	 This	 study	 highlights	 the	difficulties	in	establishing	a	validated	study	of	tumour	targeting	of	nanoparticles	with	peptides.	 In	contrast	to	the	work	of	Silva	et	al.,	Cumis	et	al.,	(2016)[84]	showed	that	Au	 conjugated	 with	 a	 tumour–homing	 peptide	 containing	 NGR	 can	 be	 targeted	 to	CD13	 receptors	 on	 tumour	 vasculature,	 suggesting	 that	 NGR-tagged	 AuNPs	 can	 be	used	 as	 a	 platform	 for	 tumour	 endothelial	 cell	 targeting	 and	 therefore	 for	 cancer	therapy.		
		
	
6	 Heating	 of	 nanoparticles:	 NPs	 have	 been	 under	 study	 as	 a	 potentially	 viable	mechanism	for	hyperthermic	tumor	treatment	for	some	time	using	two	regimes	of	the	electromagnetic	 spectrum:	 laser	 and	 radio	 frequency	 excitation.	 Aspects	 of	 NP	chemistry	which	affect	thermal	dissipation	include	the	hydrodynamic	diameter	of	the	particle,	 the	 oxidation	 state	 and	 related	 magnetism	 of	 the	 core,	 and	 the	 chemical	nature	of	 the	 ligand	 shell.	 	 There	 are	 advantages	 and	disadvantages	of	 the	different	heating	NPs	and	a	number	of	reviews	in	this	area	have	been	published.	For	example	Abaderr	 et.	 al.,(2016)[85]	 reviewed	 recent	 progress	 in	 cancer	 therapy	 using	 simple	AuNPs	for	thermal	and	radiation	enhancement	of	cancer.			
6.1	Radio	frequency	therapy:	The	RF	frequency	range	is	linked	to	the	size	of	the	NPs	and	 materials	 used	 to	 construct	 them.	 (Moran	 el.	 al.,	 2009)(Figures	 4	 and	 5)[86]	Magnetic	field	hyperthermia	can	be	made	more	effective	by	the	use	of	biocompatible	super	paramagnetic	NPs,	principally	iron.	In	principle,	these	particles	heat	cancerous	tissue	by	creating	oscillations	that	produce	heat,	although	the	mechanism	is	not	fully	understood.	Cancer	cells	could	also	be	treated	with	AuNPs,	which	have	the	advantage	that	they	are	biocompatible	and	allow	a	range	of	ligands	to	be	attached	to	them.	Bulk	gold	metal	 is	diamagnetic	but	2	nm	dodecanethiol	 (thiol)	capped	gold	nanoparticles	have	 been	 reported	 to	 exhibit	 ferromagnetism.	 This	 ferromagnetism	 is	 believed	 to	result	from	spin-orbit	coupling	between	surface-bound	thiols	and	gold	surface	atoms.	As	the	gold	nanoparticle	size	decreases	and	the	surface	area	to	volume	ratio	increases,	the	 likelihood	 of	 ferromagnetism	 increases.	 AuNPs,	 nanorods	 and	 nanoshells	 have	been	 radiated	 with	 visible	 laser	 sources	 that	 excite	 the	 particles	 at	 or	 near	 their	plasmon	resonance	 frequency,	and	this	mechanism	has	been	well	studied	(Urban	et.	al.,	 2013)	 [87]	 The	 physical	 processes	 that	 describe	 the	 experimentally	 observed	heating	at	radio	frequencies	of	13.56	MHz	are	not	fully	understood.	Differing	results	have	 been	 reported	 in	 semi-solid	 phantom	materials	 and	 liquid	 phase	 suspensions.	This	numerical	modeling	study	was	undertaken	to	inspect	the	relative	importance	of	several	candidate	physical	processes.	The	use	of	heating	to	destroy	cancer	cells	is	not	the	 only	 mechanism	 that	 could	 be	 involved.	 It	 has	 been	 suggested	 that	 RF	 excited	nanoparticles	 could	 destroy	 cancer	 cells	 by	 disrupting	 the	 Brownian	motion	 in	 the	cell.	 Aspects	 of	 RF,	which	may	 affect	 thermal	 dissipation,	 include	 power,	 frequency	and	antenna	designs	that	emphasize	relative	strength	of	magnetic	or	electric	fields.		
	
	
	
	Figure	 4	 Change	 in	 temperature	 with	 time	 of	 10	 nm	 diameter	 gold	 nanoparticle	suspensions	(circles)	and	water	alone	(squares)	exposed	to	RF	fields.		
	Figure	5.	RF	energy	absorbed	by	1.4	ppm	of	gold	nanoparticles	exhibited	a	fi	nal	Δ	T	~35	°C	in	2	min,	whereas	water	alone	exhibited	a	Δ	T	~5	°C			
The	problem	of	heating	at	lower	radio	frequencies	(RF)	has	not	been	well	elucidated	to	 this	 point,	 and	 remains	 somewhat	 controversial.	 Curley	 et.	 al.,	 2008	 [88]	 show	heating	at	13.56MHz	up	to	60	degrees,	but	a	number	of	papers	have	been	published	disputing	these	results.		
6.2	Photothermal	therapy:	A	popular	area	in	nanomedicine	is	the	implementation	of	plasmonic	 AuNPs	 for	 cancer	 diagnosis	 and	 photothermal	 therapy,	 due	 to	 their	intriguing	 optical	 properties.	 Surface	 plasmon	 resonance,	 a	 unique	 phenomenon	 of	plasmonic	(noble	metal)	nanoparticles,	produces	a	strong	electromagnetic	field	on	the	particle	 surface	 and	 consequently	 enhances	 all	 the	 radiative	 properties	 such	 as	absorption	and	scattering.	The	heating	efficiencies	and	spectral	working	ranges	vary	with	the	type	of	NP.	There	have	been	important	results	obtained	in	both	in	vivo	and	in	
vitro	NP	assisted	photothermal	 treatments.	The	results	of	photothermal	radiation	of	two	different	liver	cell	lines	exposed	to	two	different	concentrations	of	albumin	(Alb)-coated	 AuNPs.	 In	 one	 case,	 the	 Hep	 G2	 cell	 line	 exposed	 to	 the	 higher	 AuNP	concentration	 showed	 severe	 changes	 to	 intracellular	 structures;	Hep	B5	 cells	were	essentially	unaffected.	(Mocan	et.	al.,	2015)[89]			
	Figure	6.	Nanoparticles	with	different	compositions	have	been	utilized	in	theranostics	which	refers	to	therapy	and	diagnostics.			
7	Summary:	The	table	below	demonstrates	the	wide	range	of	NP	applications.	They	have	 considerable	 potential	 to	 impact	many	 areas	 of	 health	 and	will	 require	many	new	 methods	 to	 be	 developed	 to	 measure	 their	 effects	 on	 body	 functions..		Nonetheless,	 there	 are	 still	 many	 challenges	 to	 overcome	 not	 least	 the	 optimal	targeting	 of	 cells	 associated	 with	 specific	 disease	 conditions.	 Molecular	nanotechnology	 is	 a	 rapidly	 emerging	 field	 that	 will	 allow	 for	 the	 precise	 and	purposeful	 arrangement	 of	 matter	 atom	 by	 atom	 and	 eventually	 the	 building	 of	submicron-scale	medical	sensors	and	therapeutic	devices.	These	tools	could	provide	the	means	to	analyze,	understand,	and	precisely	control	 the	molecular	machinery	of	the	 human	 body,	 allowing	 the	 detection	 and	 correction	 of	 any	 undesired	 structural	changes	(disease	or	aging)	at	 the	 finest	 level	of	detail	and	the	earliest	possible	time.	Possible	 rejuvenation	 followed	 by	 the	 indefinite	 maintenance	 of	 an	 optimal	physiologic	state,	or	molecular	homeostasis,	may	ultimately	become	possible	(Wu	et.	al.,	2016)[90].		Although	 this	 review	 divides	 diagnostics	 and	 therapy	 combine	 both	 sometimes	termed	 Theranostics	 (A	 combination	 of	 diagnostics	 and	 therapy)	 as	 illustrated	 by	Figure	 6.	 Theranostics,	 refers	 to	 the	 development	 of	molecular	 diagnostic	 tests	 and	targeted	 therapeutics	 in	 an	 interdependent,	 collaborative	manner	with	 the	 goals	 of	individualizing	 treatment	 by	 targeting	 therapy	 to	 an	 individual's’	 specific	 disease	subtype	and	genetic	profile.	This	strategy	could	enable	optimization	of	drug	efficacy	and	 safety	 could	 have	 considerable	 benefit	 in	 the	 future.	 A	 key	 challenge	 is	measurement	 at	 this	 scale	 to	 assess	 the	 long-term	effects	 on	 the	 human	body.	New	technologies	are	required	to	measure	cell	physiology	in	vitro	and	toxicity.	Examples	of	some	of	the	key	papers	are	presented	in	table	1.			Table	1:	Example	of	key	papers	on	AuNP			Subject	 References	Imaging		 Shilo	et.	al.,			 Mohs	et	al.		 Liu	 et.	al,.		 Pérez-Campaña,	 et.	al.,		
Jawaid,	 P.,	et	al.		
Xing,	et	al.,		
Hainfeld	et	al.,		Chanda	et	 al.,	Mottiei	et	al.,		
Dou	 et	al.,		Point-of-Care	 Li	et.	al.,		 Yu	 et.	al.,		 Zheng	et.	al.,		Cancer		 Amed,	 M.,	et	al	 Mottiei	et	al.,		 Haynes	 et.	al.,		
Poon	 et	al.,		 Lai	 et	al.,		 Cheng	et	al.,		
Simon	 et	al.,		Irani	 et	al.,		Popovtzer	et	al.,		Song	 et	al.	,		Fitzgerald	et	al.,		Yook	 et	al.,		Delivery	 Taghdis,	 et.	al.,		 Johnstone	 et.	al.,		
Ma	 et.	al.,		 Moeendarbari	et	al.,		
Wound	healing	 and	burns	
Naraginti	et.	al.,		 Ju	et	al.,		 Volkova	 et	al.,		
Pittet	et	al.,		
Cardiovascular	disease	 Khobchandani	et.	al.,		 Xing,	 et	al.		 Jiang	et.	al	Neuroimmunology	 Jain	et.	al.,		 Shilo	et.	al.,		 Morris	et	al.,		Antibiotics	 Durán	 	 et.	al.,		 Kalita	et.	al.,		 Kalita	et	al.,			Uptake	 Huang	 et.	al.,			 Yang	et.	al.,		 Volsi	et.	al.,		Tissue	engineering	 Moravej	 et.	al.,		 Sridhar	et	al.,		 Feng	et	al.,		 Bokara	et	al.,		 Ruttledge	et	al.,		Toxicity	 Fang	et.	al.,		 Han	 et.	al.,		 Ze	 et.	al.,		 Song	et.	al.,		 Xu	et.	al.,		 Li	et.	al.,		 Perreault	et	al.,		Gromnic
ova	 R,	 et	al.,		Syed	 et	al.,		Negahdary	et	al.,		Vandebriel	et	al.,		Naz	et	al.,		Heating	 Irani	et.	al.,		 Curley	et.	al.,		 Abaderr	 et.	al.,		
Dou	 et.	al.,		 Moran	 et	al.,		
Urban	 et	al.,	
Gomaa	 et	al.,				
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